Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1979 Sep;96(3):799–810.

A possible role of arachidonic acid in human neutrophil aggregation and degranulation.

J T O'Flaherty, H J Showell, P A Ward, E L Becker
PMCID: PMC2042398  PMID: 474719

Abstract

Chemotactic factors stimulate neutrophils to aggregate and, in the presence of cytochalasin B, to degranulate. Recently, the authors found that arachidonic acid also stimulates human neutrophils to aggregate but does not stimulate cytochalasin-B-treated or untreated cells to degranulate. In this report the authors examined the effect of three blockers of arachidonic acid metabolism on these cellular responses. It was found that the arachidonic acid analog 5,8,11,14-eicosatetraynoic acid and indomethacin, but not aspirin, inhibited no only the arachidonic-acid-induced aggregation response but also the degranulation responses evoked by C5a or a synthetic oligopeptide chemotactic factor. These results suggest that arachidonic acid may be a precursor of bioactive metabolites that stimulate the aggregation and foster the degranulation responses of neutrophils. Thus, these metabolites may be mediators of neutrophil function. Agents that block their formation may thereby inhibit aggregation and degranulation.

Full text

PDF
799

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aswanikumar S., Corcoran B., Schiffmann E., Day A. R., Freer R. J., Showell H. J., Becker E. L. Demonstration of a receptor on rabbit neutrophils for chemotactic peptides. Biochem Biophys Res Commun. 1977 Jan 24;74(2):810–817. doi: 10.1016/0006-291x(77)90375-8. [DOI] [PubMed] [Google Scholar]
  2. Borgeat P., Hamberg M., Samuelsson B. Transformation of arachidonic acid and homo-gamma-linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxy acids from novel lipoxygenases. J Biol Chem. 1976 Dec 25;251(24):7816–7820. [PubMed] [Google Scholar]
  3. Bunting S., Higgs G. A., Moncada S., Vane J. R. Generation of thromboxane A2-like activity from prostaglandin endoperoxides by polymorphonuclear leukocyte homogenates [proceedings]. Br J Pharmacol. 1976 Oct;58(2):296P–296P. [PMC free article] [PubMed] [Google Scholar]
  4. Chenoweth D. E., Hugli T. E. Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3943–3947. doi: 10.1073/pnas.75.8.3943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fernandez H. N., Hugli T. E. Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a. J Immunol. 1976 Nov;117(5 Pt 1):1688–1694. [PubMed] [Google Scholar]
  6. Goetzl E. J., Gorman R. R. Chemotactic and chemokinetic stimulation of human eosinophil and neutrophil polymorphonuclear leukocytes by 12-L-hydroxy-5,8,10-heptadecatrienoic acid (HHT). J Immunol. 1978 Feb;120(2):526–531. [PubMed] [Google Scholar]
  7. Goetzl E. J., Woods J. M., Gorman R. R. Stimulation of human eosinophil and neutrophil polymorphonuclear leukocyte chemotaxis and random migration by 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid. J Clin Invest. 1977 Jan;59(1):179–183. doi: 10.1172/JCI108617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Goldstein I. M., Malmsten C. L., Kindahl H., Kaplan H. B., Rådmark O., Samuelsson B., Weissmann G. Thromboxane generation by human peripheral blood polymorphonuclear leukocytes. J Exp Med. 1978 Sep 1;148(3):787–792. doi: 10.1084/jem.148.3.787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Goldstein I. M., Malmsten C. L., Samuelsson B., Weissmann G. Prostaglandins, thromboxanes, and polymorphonuclear leukocytes: mediation and modulation of inflammation. Inflammation. 1977 Dec;2(4):309–317. doi: 10.1007/BF00921010. [DOI] [PubMed] [Google Scholar]
  10. Higgs G. A., Bunting S., Moncada S., Vane J. R. Polymorphonuclear leukocytes produce thromboxane A2-like activity during phagocytosis. Prostaglandins. 1976 Nov;12(5):749–757. doi: 10.1016/0090-6980(76)90050-2. [DOI] [PubMed] [Google Scholar]
  11. Higgs G. A., McCall E., Youlten L. J. A chemotactic role for prostaglandins released from polymorphonuclear leucocytes during phagocytosis. Br J Pharmacol. 1975 Apr;53(4):539–546. doi: 10.1111/j.1476-5381.1975.tb07392.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hill H. R., Estensen R. D., Quie P. G., Hogan N. A., Goldberg N. D. Modulation of human neutrophil chemotactic responses by cyclic 3',5'-guanosine monophosphate and cyclic 3',5'-adenosine monophosphate. Metabolism. 1975 Mar;24(3):447–456. doi: 10.1016/0026-0495(75)90124-9. [DOI] [PubMed] [Google Scholar]
  13. Kaley G., Weiner R. Effect of prostaglandin E 1 on leukocyte migration. Nat New Biol. 1971 Nov 24;234(47):114–115. doi: 10.1038/newbio234114a0. [DOI] [PubMed] [Google Scholar]
  14. Kinlough-Rathbone R. L., Reimers H. J., Mustard J. F., Packham M. A. Sodium arachidonate can induce platelet shape change and aggregation which are independent of the release reaction. Science. 1976 Jun 4;192(4243):1011–1012. doi: 10.1126/science.1273582. [DOI] [PubMed] [Google Scholar]
  15. Kitchen E. A., Boot J. R., Dawson W. Chemotactic activity of thromboxane B2, prostaglandins and their metabolites for polymorphonuclear leucocytes. Prostaglandins. 1978 Aug;16(2):239–244. doi: 10.1016/0090-6980(78)90025-4. [DOI] [PubMed] [Google Scholar]
  16. Lüscher E. F. Mechanism of platelet function with particular reference to the effects of drugs acting as inhibitors. Agents Actions. 1978 Apr;8(3):282–290. doi: 10.1007/BF01966616. [DOI] [PubMed] [Google Scholar]
  17. Mason R. J., Stossel T. P., Vaughan M. Lipids of alveolar macrophages, polymorphonuclear leukocytes, and their phagocytic vesicles. J Clin Invest. 1972 Sep;51(9):2399–2407. doi: 10.1172/JCI107052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. McCall E., Youlten L. J. Proceedings: Prostaglandin E1 synthesis by phagocytosing rabbit polymorphonuclear leucocytes: its inhibition by indomethacin and its role in chemotaxis. J Physiol. 1973 Oct;234(2):98P–100P. [PubMed] [Google Scholar]
  19. O'Flaherty J. T., Kreutzer D. L., Showell H. J., Vitkauskas G., Becker E. L., Ward P. A. Selective neutrophil desensitization to chemotactic factors. J Cell Biol. 1979 Mar;80(3):564–572. doi: 10.1083/jcb.80.3.564. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. O'Flaherty J. T., Kreutzer D. L., Ward P. A. Chemotactic factor influences on the aggregation, swelling, and foreign surface adhesiveness of human leukocytes. Am J Pathol. 1978 Mar;90(3):537–550. [PMC free article] [PubMed] [Google Scholar]
  21. O'Flaherty J. T., Showell H. J., Becker E. L., Ward P. A. Neutrophil aggregation and degranulation. Effect of arachidonic acid. Am J Pathol. 1979 May;95(2):433–444. [PMC free article] [PubMed] [Google Scholar]
  22. O'Flaherty J. T., Showell H. J., Becker E. L., Ward P. A. Substances which aggregate neutrophils. Mechanism of action. Am J Pathol. 1978 Jul;92(1):155–166. [PMC free article] [PubMed] [Google Scholar]
  23. O'Flaherty J. T., Showell H. J., Kreutzer D. L., Ward P. A., Becker E. L. Inhibition of in vivo and in vitro neutrophil responses to chemotactic factors by a competitive antagonist. J Immunol. 1978 Apr;120(4):1326–1332. [PubMed] [Google Scholar]
  24. Sahu S., Lynn W. S. Lipid chemotaxins isolated from culture filtrates of Escherichia coli and from oxidized lipids. Inflammation. 1977 Mar;2(1):47–54. doi: 10.1007/BF00920874. [DOI] [PubMed] [Google Scholar]
  25. Samuelsson B., Folco G., Granström E., Kindahl H., Malmsten C. Prostaglandins and thromboxanes: biochemical and physiological considerations. Adv Prostaglandin Thromboxane Res. 1978;4:1–25. [PubMed] [Google Scholar]
  26. Silver M. J., Smith J. B., Ingerman C., Kocsis J. J. Arachidonic acid-induced human platelet aggregation and prostaglandin formation. Prostaglandins. 1973 Dec;4(6):863–875. doi: 10.1016/0090-6980(73)90121-4. [DOI] [PubMed] [Google Scholar]
  27. Smith J. B., Willis A. L. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol. 1971 Jun 23;231(25):235–237. doi: 10.1038/newbio231235a0. [DOI] [PubMed] [Google Scholar]
  28. Smolen J. E., Shohet S. B. Remodeling of granulocyte membrane fatty acids during phagocytosis. J Clin Invest. 1974 Mar;53(3):726–734. doi: 10.1172/JCI107611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Stossel T. P., Mason R. J., Smith A. L. Lipid peroxidation by human blood phagocytes. J Clin Invest. 1974 Sep;54(3):638–645. doi: 10.1172/JCI107801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Tainer J. A., Turner S. R., Lynn W. S. New aspects of chemotaxis. Specific target-cell attraction by lipid and lipoprotein fractions of Escherichia coli chemotactic factor. Am J Pathol. 1975 Nov;81(2):401–410. [PMC free article] [PubMed] [Google Scholar]
  31. Turner S. R., Campbell J. A., Lynn W. S. Polymorphonulcear leukocyte chemotaxis toward oxidized lipid components of cell membranes. J Exp Med. 1975 Jun 1;141(6):1437–1441. doi: 10.1084/jem.141.6.1437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Turner S. R., Tainer J. A., Lynn W. S. Biogenesis of chemotactic molecules by the arachidonate lipoxygenase system of platelets. Nature. 1975 Oct 23;257(5528):680–681. doi: 10.1038/257680a0. [DOI] [PubMed] [Google Scholar]
  33. Valone F. H., Goetzl E. J. Immunologic release in the rat peritoneal cavity lipid chemotactic and chemokinetic factors for polymorphonuclear leukocytes. J Immunol. 1978 Jan;120(1):102–108. [PubMed] [Google Scholar]
  34. Van Epps D. E., Bankhurst A. D., Williams R. C., Jr Casein-mediated neutrophil chemotaxis: a parallel between surface binding and chemotaxis. Inflammation. 1977 Jun;2(2):115–123. doi: 10.1007/BF00918673. [DOI] [PubMed] [Google Scholar]
  35. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  36. Vargaftig B. B., Zirinis P. Platelet aggregation induced by arachidonic acid is accompanied by release of potential inflammatory mediators distinct from PGE2 and PGF2. Nat New Biol. 1973 Jul 25;244(134):114–116. doi: 10.1038/newbio244114a0. [DOI] [PubMed] [Google Scholar]
  37. Williams L. T., Snyderman R., Pike M. C., Lefkowitz R. J. Specific receptor sites for chemotactic peptides on human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A. 1977 Mar;74(3):1204–1208. doi: 10.1073/pnas.74.3.1204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Willis A. L. An enzymatic mechanism for the antithrombotic and antihemostatic actions of aspirin. Science. 1974 Jan 25;183(4122):325–327. doi: 10.1126/science.183.4122.325. [DOI] [PubMed] [Google Scholar]
  39. Willis A. L., Kuhn D. C., Weiss H. J. Acetylenic analog of arachidonate that acts like aspirin on platelets. Science. 1974 Jan 25;183(4122):327–330. doi: 10.1126/science.183.4122.327. [DOI] [PubMed] [Google Scholar]
  40. Zurier R. B. Prostaglandin release from human polymorphonuclear leukocytes. Adv Prostaglandin Thromboxane Res. 1976;2:815–818. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES